All Updates

All Updates

icon
Filter
Product updates
AbCellera partners with EQRx and Tachyon Therapeutics on novel therapeutics
AI Drug Discovery
Aug 4, 2021
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Product updates
Funding
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Aug 4, 2021

AbCellera partners with EQRx and Tachyon Therapeutics on novel therapeutics

Product updates

  • Canadian AI drug discovery company AbCellera has partnered with two US-based biotechnology companies EQRx and Tachyon Therapeutics, to jointly discover and develop novel antibodies. The terms and financial details of the collaborations have not been disclosed.

  • The collaboration with EQRx will focus on multiple therapeutic areas and will initially commence with identifying novel antibody drug candidates for oncology and immunology. For this purpose, AbCellera will investigate natural immune responses, by leveraging its artificial intelligence (AI) based antibody discovery platform. AbCellera will also support EQRx in expanding its early-stage pipeline of drug candidates.

  • The collaboration with Tachyon therapeutics will focus on developing therapeutic antibodies to treat cancer-targeting LEFTY1, a protein-coding gene, and a member of the transforming growth factor beta (TGF-beta) superfamily. AbCellera is eligible to receive milestone and royalty payments for products developed via its antibody discovery platform. 

  • As a part of both agreements, AbCellera has the option of investing in progressive stages of the drug development process in exchange for an increased share of product sales proceeds. 

  • Founded in 2012, AbCellera operates its proprietary AI-powered antibody discovery platform to discover and develop therapeutic antibodies that can be used as a treatment for various diseases, including cancer, neurodegeneration, and infections such as influenza and Covid-19. The company has established partnerships with Eli Lilly, GSK, Novartis, Pfizer, and Sanofi. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.